Latest Breaking News On - Sagimet biosciences - Page 1 : vimarsana.com

Platinum Investment Management Ltd. Has $606,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)

Platinum Investment Management Ltd. lowered its position in Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) by 70.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 111,752 shares of the company’s stock after selling 272,161 shares during the period. Platinum Investment Management Ltd. owned 0.52% of Sagimet Biosciences […]

Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) in a research report released on Friday morning, Benzinga reports. The brokerage currently has a $32.00 target price on the stock. Several other brokerages also recently issued reports on SGMT. Leerink Partnrs reissued an outperform rating on shares of Sagimet […]

Sagimet Biosciences' (SGMT) "Market Outperform" Rating Reaffirmed at JMP Securities

JMP Securities reissued their market outperform rating on shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $48.00 target price on the stock. Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a buy rating […]

Sagimet Biosciences' (SGMT) "Market Outperform" Rating Reaffirmed at JMP Securities

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Buy" by Analysts

Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock […]

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase ...

SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

SAN MATEO, Calif., May 06, 2024 Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic.

Wall Street Breakfast Podcast: Dave & Buster's Arcade Betting